Destiny Pharma Holdings plc (DEST) Ord GBP0.01
Share news, reports & tips
7 September 2020 08:57
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has entered into a collaboration agreement with SporeGen, it announced on Monday, which is a UK biotechnology company working on...
11 August 2020 12:18
(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced a positive interim safety review of the ongoing phase 2b study of its lead asset 'XF-73' in the prevention of...
9 June 2020 15:51
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has been jointly awarded a National Biofilms Innovation Centre (NBIC) grant to fund a research collaboration with Cardiff University, it...
16 October 2019 14:48
(Sharecast News) - Clinical stage biotechnology company Destiny Pharma reported on the publication of results from a positive phase 1 clinical study in 60 healthy United States volunteers using a nasal gel...
9 April 2019 09:32
(Sharecast News) - Destiny Pharma on Tuesday reported a wider annual loss as it increased research and development costs, although the company is "well funded" through to the second half of next year.
28 January 2019 10:39
(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive data and the non-irritant classification for its XF-73 nasal gel on Monday.
25 January 2019 10:58
(Sharecast News) - Destiny Pharma jumped on Friday after being awarded funding of up to £1.6m from a collaboration established under the UK-China AMR grant fund.
19 October 2018 14:54
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma noted the launch of a series of videos and explainer documents from the UK BioIndustry Association (BIA) celebrating UK bioscience and...
6 September 2018 10:32
(Sharecast News) - Clinical stage biotechnology firm Destiny Pharma revealed on Thursday that long-time chairman Nigel Rudd was stepping down from the board on 31 December after eight years.
12 April 2018 12:12
(ShareCast News) - Antimicrobial development firm Destiny Pharma reported an increase in losses over the year ending 31 December, with pretax loss increasing 113% to £3.2m.
15 March 2018 09:55
(ShareCast News) - Destiny Pharma has been granted fast-track designation by the US drug regulator for its lead clinical candidate.
1 December 2017 15:43
(ShareCast News) - Clinical stage biotechnology company Destiny Pharma announced on Friday that China Medical System Holdings has, through its wholly owned subsidiary CMS Medical Venture Investment, invested...
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2020. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.